Kator Sarah, Correll Darin J, Ou Judy Y, Levinson Radmila, Noronha Genevieve N, Adams Christopher D
Department of Pharmacy, Mayo Clinic, Rochester, MN
Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Am J Health Syst Pharm. 2016 Mar 1;73(5 Suppl 1):S22-9. doi: 10.2146/ajhp150367.
The results of a study evaluating all patients treated with adjunctive low-dose ketamine for analgesia over a three-year period are presented.
A retrospective single-center analysis evaluated all adult patients who received adjunctive low-dose i.v. ketamine infusions from September 2010 to September 2013. Patients were excluded if they received concomitant oral ketamine, if ketamine was used to treat seizures, or if the patients received ketamine boluses without infusion. The primary endpoint was to identify the patient populations receiving low-dose intravenous ketamine. Secondary endpoints included an assessment of clinical variables and adverse events. Demographic information, level of care, clinical variables, adverse events, and patient outcomes were recorded.
A total of 460 patients were evaluated. Of these, 396 were included in this analysis. Ketamine was administered to 69.9% of the patients in association with a surgical procedure, as opposed to 30.1% who received ketamine for medical management of pain. The percentage of patients receiving intensive care unit level care was 24%. Before initiation of ketamine, patient-reported pain scores averaged 7.1 ± 2.63 S.D.; during the ketamine infusion, patient-reported pain scores averaged 6.42 ± 2.01 S.D.; (p < 0.001). In the safety analysis, hypertension occurred in 21.4% of patients, hypotension occurred in 15.1% of patients, and respiratory depression occurred in 6.3% of patients.
A retrospective review found that patients receiving continuous ketamine infusions in addition to opioid therapy saw a reduction in pain scores and experienced cardiovascular adverse effects in greater than 20% of cases.
本文呈现了一项为期三年的研究结果,该研究评估了所有接受辅助低剂量氯胺酮镇痛治疗的患者。
一项回顾性单中心分析评估了2010年9月至2013年9月期间所有接受辅助低剂量静脉注射氯胺酮输注的成年患者。如果患者同时接受口服氯胺酮、使用氯胺酮治疗癫痫或接受了未进行输注的氯胺酮推注,则将其排除。主要终点是确定接受低剂量静脉氯胺酮治疗的患者群体。次要终点包括临床变量和不良事件的评估。记录了人口统计学信息、护理水平、临床变量、不良事件和患者结局。
共评估了460例患者。其中,396例纳入本分析。69.9%的患者在手术过程中使用了氯胺酮,而30.1%的患者使用氯胺酮进行疼痛的药物治疗。接受重症监护病房护理水平的患者比例为24%。在开始使用氯胺酮之前,患者报告的疼痛评分平均为7.1±2.63标准差;在氯胺酮输注期间,患者报告的疼痛评分平均为6.42±2.01标准差;(p<0.001)。在安全性分析中,21.4%的患者出现高血压,15.1%的患者出现低血压,6.3%的患者出现呼吸抑制。
一项回顾性研究发现,除阿片类药物治疗外,接受持续氯胺酮输注的患者疼痛评分降低,且超过20%的病例出现心血管不良反应。